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Introduction    
INTRODUCTION 
Diabetes Mellitus is a common and a serious disease with chronic 
complications and constitutes a substantial burden for both patient and 
health care system. In 2010, the global prevalence of diabetes was 
estimated at 285 million, corresponding to 6.4% of world’s adult 
population. This figure is predicted to reach 438 million by 2030 as a 
consequence of longer life expectancy, sedentary life style and changing 
dietary patterns. According to recent estimates, presently India has 32 
million diabetic subjects, and this is projected to increase to 100million 
i.e. rise by 250% by the year 2035. In the CUPS (Chennai urban 
population) study by Mohan et al, 12% of individuals above age of 20 
years in Chennai were found to be diabetic in the year 1997. In the more 
recent CURES study, conducted on 26,001 individuals showed that 16% 
now have diabetes in Chennai. 
1,2,3
 
Vascular complications both micro and macrovascular predominate 
the features of Indian diabetes due to delayed diagnosis. Various 
microvascular complications in diabetes mellitus includes 
• Diabetic Retinopathy 
• Diabetic Nephropathy 
• Diabetic Neuropathy 
Presence of microvascular complications at the time of diagnosis of 
diabetes mellitus are showing increasing trend in India. Early detection of 
microvascular complications and its treatment at this time by intensive 
therapy can prevent progression of these complications and hence 
morbidity and mortality among patients. 
Diabetic Neuropathy is one of the most common troublesome 
complications of diabetes mellitus. The prevalence of neuropathy is 
related to age, duration of diabetes and the quality of metabolic control, 
by the time a diabetic patient has severe neuropathy, retinopathy and 
albuminuria are also usually present. Diabetic neuropathy is clinically 
present in 30-50% of all diabetes patients. Diabetic foot accounts for one 
of the largest inpatients admissions in India.
4,5
  
The primary pathological role of hyperglycemia in diabetic 
complications is well established. With the increasing knowledge that 
maintenance of euglycemia greatly reduces, if not prevents the risk of 
diabetic complications and at times helps even in regression of such 
complications, monitoring the control of diabetes is essential for the 
successful management of the diabetes
6
.  
Keontg and Gabbay and their co-workers have suggested 
measurement of glycosylated hemoglobin (HbA1C) as an indicator of 
diabetic control. HbA1C is formed by the post-transcriptional 
glycosylation of HbA at the amino-terminal valine of Beta chain. When 
properly assayed HbA1C level in a blood sample gives an estimate of 
diabetic control for preceding 3-4 month period (i.e. life span of RBC)
7,8
. 
DCCT study proved that a glycated Hemoglobin (HbA1C) reduction 
from 9 to 7% for a mean follow up of 6.5 years was able both to reduce 
the onset of diabetic neuropathy (from 9.6% 2.8%) and to slow its 
progression. However, euglycemia is only able to halt the progression, 
rather than reverse it, once the nerve damage is established.
9,10
 
The relative effect of cardiovascular risk factors specifically
 
associated with diabetes (e.g., hypertension, dyslipidemia,
 
and increased 
weight) or not associated with diabetes (smoking)
 
on the development of 
neuropathy are incompletely elucidated.
 
The Diabetes Control and 
Complications Trial (DCCT) reported
 
a 60 percent reduction in 
neuropathy in the intensively treated
 
groups after five years but the 
cumulative incidence of neuropathy
 
(15 to 21 percent) and abnormal 
nerve conduction (40 to 52 percent)
 
remained substantial. Such findings 
suggest that neuropathy
 
can develop, despite intensive control of the 
glucose level.Thus, risk factors besides hyperglycemia are probably 
involved
 
in the evolution of neuropathy.
9,10
 Identifying them, particularly
 
if they are modifiable, might lead to new risk-reduction strategies.
 
The 
European Diabetes (EURODIAB) Prospective Complications Study
 
aimed to define and assess the relative importance of other,
 
potentially 
modifiable factors that increase the risk of distal
 
symmetric neuropathy in 
patients with type 1 diabetes mellitus.
 
 
The present  study aims to evaluate peripheral neuropathy in type 
2 diabetes patients by clinical examination and  electrophysiologicaly by 
nerve conduction studies  and to correlate it with the other 
microvascular complications and various risk factors  such as age, sex, 
duration of diabetes, HbA1C, body mass index, systemic hypertension  
and hypercholesterolemia. The importance of this study lies in the fact 
that the morbidity and mortality in diabetes is attributed to a large 
extend by its complications. Early detection and treatment of these 
complications therefore plays a crucial role. Other than glycemic control, 
there are no treatments
 
for diabetic neuropathy. Thus, identifying 
potentially modifiable
 
risk factors for neuropathy is crucial. Detecting 
these risk factors helps in correcting these at an early stage. Correlation 
between the various microvascular complications helps in better 
understanding of their pathogenesis and early control. 
 
 
  
 
 
 
Aims & Objectives          
AIMS AND OBJECTIVES 
 
 To evaluate peripheral neuropathy in type 2 diabetes patients by 
clinical examination and electrophysiologicaly by nerve 
conduction study and thus do a comparative analysis. 
 
 To study the correlation of diabetic peripheral neuropathy with 
other microvascular complications by assessing microalbuminuria 
and retinopathy. 
 
 To study the correlation of diabetic peripheral neuropathy with 
age, sex, duration of diabetes, body mass index, systemic 
hypertension and  total serum cholesterol. 
 
 
 
 
                                                 
  
 
 
 
Review of Literature            
REVIEW OF LITERATURE 
“To know diabetes is to know medicine”
 
Historic Review 
Knowledge of diabetes dates back to Centuries before Christ. The 
Egyptian PAPYRUS EBCRS (Ca.1500 B.C) described an illness 
associated with the passage of much urine. First clear clinical description 
was given by CELSUS in the first century (30BC to 50 A.D).  
The word “DIABETES” coined by ARETAEUS, of 
CAPPADOCIA probably derived from Greek work Indicating “Running 
Through as a Siphon”. “because the fluid does not remain in the body but 
uses the man’s body as a ladder whereby to leave it”. The disease is better 
understood in India. CHARAKA (2
nd 
century AD) in his “Charaka 
Samhita” has mentioned the sweetness of urine in addition to the 
symptom of polyuria. The ancient Indian surgeon Sushruta (500 AD) 
described the disease as “Madhu Meha” (Honey Urine) with symptoms of 
polyphagia, polydypsia and polyuria. Avicenna (980–1037), an Arab 
Physician gave the first description of diabetic gangrene. FREDRICK-
BANTING AND CHARLES BEST discovered insulin in 1922.  
JOHN ROLLO IN 1978 recorded the involvement of Nervous 
system in diabetes. MARACHAL DE CALVI (1864) first suggested that 
diabetes might be the cause rather than the effect of Neuropathy.  
PAVY (1885) gave a detailed description of the clinical 
manifestation of diabetic neuropathy. R.W. RUNNDLES wrote that 
entire nervous system may be involved including central, autonomic and 
peripheral systems, but more commonly peripheral system. JORDON 
(1936) AND RUDDLES (1945) gave the first clear description of 
autonomic neuropathy.  
IN 1936, Jordon tried to classify the neurological manifestation into 3 
groups.  
1. Hyperglycemic symptoms-Reversed upon treatment.  
2. Circulatory degenerative type  
3. Neurotic type  
THOMAS AND LESCELLES (1966) described an increased 
incidence of segmental demyclination in diabetic Neuropathy. BISHOP 
(1968) postulated that a disordered lipid metabolism in the Schwann cells 
results in demyelination.  In monitoring the control of diabetes, 
estimation of urine sugar and blood sugar have drawback as it requires 
patient compliance and  frequent measurements.  
Consequently GABBAY et al, 
 
in 1976 suggested measurement of 
Glycosylated hemoglobin as an indicator of diabetic control 
15,16 
 
 
Diabetes Mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia, resulting from defects in insulin secretion, insulin action 
or both. The metabolic dysregulation associated with diabetes mellitus 
causes secondary pathophysiological changes in multiple organ systems. 
With an increasing incidence world wide, diabetes mellitus will be the 
leading cause of morbidity and mortality in the future. 
Etiologic classification of diabetes mellitus
17
 
1.  Type 1 Diabetes (β-cell destruction, usually leading to absolute 
insulin deficiency). 
A.  Immune mediated 
B.  Idiopathic 
2.  Type 2 diabetes (may range from predominantly insulin resistance 
with relative insulin deficiency to a predominantly insulin secretory 
defect with insulin resistance). 
3.  Other specific types of diabetes 
     A. Genetic defects of β-cell function characterized by mutation in: 
• Hepatocyte Nuclear Transcription Factor (HNF) 4α (MODY 1) 
• Glucokinase (MODY 2) 
• HNF-1α (MODY 3) 
• Insulin promoter factor (IPF) 1 (MODY 4) 
• HNF-1β (MODY 5) 
• Neuro D1 (MODY 6) 
• Mitochondrial DNA 
• Proinsulin or insulin conversion 
Genetic defects in insulin action 
1.  Type A insulin resistance 
2.  Leprechaunism 
3.  Rabson Mendenhall syndrome 
4.  Lipodystrophy syndromes 
B.  Diseases of the exocrine pancreas–pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy. 
C.  Endocrinopathies–acromegaly, Cushing’s syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, 
aldosteronoma. 
D.  Drug or chemical induced–Vacor, pentamidine, nicotinic acid, 
glucocorticoids, thyroid hormone, diazoxide, beta – adrenergic 
agonists, thiazides, phenytoin, α-interferon, protease inhibitors, 
clozapine, β-blockers. 
E.  Infections – congenital rubella, cytomegalovirus, coxsackie. 
F. Uncommon forms of immune mediated diabetes–“stiff-man” 
syndrome, anti-insulin receptor antibodies. 
G. Other genetic syndromes sometimes associated with diabetes. 
Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, 
wolfram’s syndrome, Friedreich’s ataxia, Huntington’s chorea, 
Laurence Moon Biedl Syndrome, myotonic dystrophy, porphyria, 
Prader – Willi syndrome. 
4. Gestational Diabetes 
Diagnostic criteria for diabetes mellitus
17
 
The criteria for diagnosis of diabetes are shown in the table: 
DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS 
• Symptoms of diabetes plus  random blood glucose concentration 
≥11.1 mmol/L (200 mg/dL)
a 
or 
• Fastng plasma glucose ≥ 7.0 mol/L (126 mg/dL)
b
 or 
• Two-hour plasma glucose ≥ 11.1 mmol/L (200 mg/dL) during an 
oral glucose tolerance test 
c
 
 
Three ways to diagnose diabetes are possible and each, in the 
absence of unequivocal hyperglycemia, must be confirmed, on a 
subsequent day by any one of the 3 methods, given in the table. The use 
of the hemoglobin A1C (HbA1C) for the diagnosis of diabetes is not 
recommended at this time. 
COMPLICATIONS OF DIABETES 
Diabetes has both acute and long-term complications. They are : 
Acute 
• Diabetic ketoacidosis 
• Hyperglycemic hyperosmolar state 
• Hypoglycemia 
Long term 
• Retinopathy 
• Neuropathy 
• Nephropathy 
• Ischemic heart disease 
• Cerebrovascular disease 
• Peripheral vascular disease 
Others 
• Infections 
  UTI 
  Tuberculosis 
  Candidiasis – Oral / Vulvovaginal 
  Mucormycosis 
  Necrotising fasciitis 
  Periodontitis 
Microvascular complications in Diabetes Mellitus 
All forms of diabetes, both  inherited and acquired, are 
characterized by hyperglycemia, a relative or absolute lack of insulin, and 
the development of diabetes specific microvascular pathology in the 
retina, renal glomerulus, and peripheral nerve. 
Pathogenesis 
Diabetes mellitus causes both microvascular and macrovascular 
complications. It has been showed in studies that microvascular 
complications are mainly because of hyperglycemia, whereas insulin 
resistance is the major determinant in macrovascular disease. 
Atherosclerosis is the pathological entity in macrovascular disease. 
Microvascular complications are due to following mechanisms
18
 
Most cells are able to reduce the transport of glucose inside the cell 
when they are exposed to hyperglycemia, so that their internal glucose 
concentration stays constant. In contrast, the cells damaged by 
hyperglycemia are those that cannot do this efficiently. 
Thus, diabetes selectively damages cells, like endothelial cells and 
mesangial cells. 
i. Myoinositol Metabolism  
  Glucose acts a virtually the sole source of energy in peripheral 
nerves as well as in the brain. It enters nerve cells through insulin – 
independent pathways and is used in the production of ATP. Although, 
ATP production does not appear impaired, experimental diabetic nerves 
do demonstrate a reduction in ATP utilization, thought to be secondary to 
decrease Na/K ATPase activity. Decreased Na/K ATPase activity has 
been shown to correlate to decreased myoinositol concentrations within 
peripheral nerves in diabetic animals.  
Myoinositol is a normal dietary hexose having structural similarity 
to glucose. It is an important constituent of phospholipid and cell 
membrane, is 90 to 100 times more concentrated in peripheral nerves than 
in plasma. 
 Hyperglycemia results in competitive inhibition of the sodium- 
dependent transport system responsible for myoinositol uptake. This 
decreased uptake is hypothesized to contribute to the decreased 
concentration of myo-inositol found in the peripheral nerve, as well as 
decreased Na/K ATPase activity. Na/K ATPase impairment not only 
results in decreased nerve cell membrane potential and, therefore 
decreased nerve conduction, but also decreased sodium dependent myo-
inositol uptake creating a worsening cycle. Myo-inositol replacement 
restores the normal nerve function. 
 
Increased flux through the polyol pathway 
The polyol pathway focuses on the enzyme aldose reductase. 
Aldose reductase normally has the function of reducing toxic aldehydes 
in the cell to inactive alcohols, but when the glucose concentration in the 
cell becomes too high, aldose reductase also reduces that glucose to 
sorbitol, which is later oxidized to fructose. In the process of reducing 
high intracellular glucose to sorbitol, the aldose reductase consumes the 
cofactor NADPH. NADPH is also the essential cofactor for regenerating 
a critical intracellular antioxidant, reduced glutathione. By reducing the 
amount of reduced glutathione, the polyol pathway increases 
susceptibility to intracellular oxidative stress. 
 
 
 
 
 
 
Intracellular production of advanced glycation endproducts (AGE)- 
It is harmful by three mechanisms 
The first mechanism, is the modification of  intracellular proteins 
including, most importantly, proteins involved in the regulation of gene 
transcription 
NADPH NADPH 
Glucose  
Aldose 
Reductase  
NAD+ NADP 
Sorbitol 
Dehydogenase 
Sorbitol 
Water accumulation  
Change in ionic gradients 
Axonal constriction  
Schwann cell malfunction  
Neuronal degeneration  
Fructose  
1. Glycosylated nerve protein – alteration in myelin macrophage   
interaction – segmental demyelination.
35 
 
2. Glycosylated protein in RBC membrane – decreased RBC 
deformability  and Gly. Serum protein – Hyperviscosity -- Tissue 
hypoxia – Nerve    dysfunction.  
3. Glycosylated Hemoglobin – greater affinity for oxygen – Tissue 
hypoxia – nerve dysfunction (Ditizel and Strandl, 1975).  
Second mechanism, is that these AGE precursors can diffuse out of 
the cell and modify extracellular matrix molecules nearby, which changes 
signaling between the matrix and the cell and causing cellular 
dysfunction. . Advanced glycation end products have been shown to have 
an effect on matrix metalloproteinases, which might damage nerve fibers 
The third mechanism is that these AGE precursors diffuse out of the cell 
and modify circulating proteins in the blood such as albumin. These 
modified circulating proteins can then bind to AGE receptors and activate 
them, thereby causing the production of inflammatory cytokines and 
growth factors, which in turn cause vascular pathology 
Protein kinase activation (PKC activation) 
Hyperglycemia inside the cell increases the synthesis of a molecule 
called diacylglycerol, which is a critical activating cofactor for the classic 
isoforms of protein kinase. When PKC is activated by intracellular 
hyperglycemia, it has a variety of effects on gene expression. In each 
case, the things that are good for normal function are decreased and the 
things that are bad are increased. For example, the vasodilator producing 
endothelial nitric oxide (NO) synthase (eNOS) is decreased, while the 
vasoconstrictor endothelin-1 is increased. 
Increased hexosamine pathway activity 
Next mechanism is increased flux through the hexosamine 
pathway. When glucose is high inside a cell, most of that glucose is 
metabolized through glycolysis,going first to glucose-6 phosphate, then 
fructose-6 phosphate, and then on through the rest of the glycolytic 
pathway. However, some of that fructose-6-phosphate gets diverted into 
signaling pathway in which an enzyme called GFAT (glutamine fructose-
6 phosphate amidotransferase) converts the fructose-6 phosphate to 
glucosamine-6 phosphate and finally to UDP (uridine diphosphate) N-
acetyl glucosamine. The N-acetyl glucosamine gets put onto serine and 
threonine residues of transcription factors, just like the more familiar 
process of phosphorylation, and over modification by this glucosamine 
often results in pathologic changes in gene expression. For example, 
increased modification of the transcription factor Sp1 results in increased 
expression of transforming growth factor ß1 and plasminogen activator 
inhibitor-1, both of which are bad for diabetic blood vessels. 
Hyperglycemia increases superoxide production by the mitochondria 
and causes oxidative stress on the cells 
In diabetic cells with high glucose inside, there is more glucose 
being oxidized in the TCA cycle, which, in effect, pushes more electron 
donors (NADH and FADH2) into the electron transport chain. As a result 
of this, the voltage gradient across the mitochondrial membrane increases 
until a critical threshold is reached. At this point, electron transfer inside 
complex III is blocked, causing the electrons to back up to coenzyme Q, 
which donates the electrons one at a time to molecular oxygen, thereby 
generating superoxide. 
Mitochondrial overproduction of superoxide activates the four 
major pathways of hyperglycemic damage by inhibiting GAPDH. This is 
the key pathway, which activates all other pathways thus unifying the 
mechanism. 
Macrovascular Pathogenesis 
For microvascular disease end points, there is a nearly 10-fold 
increase in risk as HbA1C increases from 5.5 to 9.5%. In contrast, over 
the same HbA1C range, macrovascular risk increases only about twofold. 
Hence hyperglycemia is not the major determinant of diabetic 
macrovascular disease. 
Insulin resistance is the main pathophysiologic abnormality found 
in these patients. Insulin resistance causes mitochondrial overproduction 
of ROS in macrovascular endothelial cells by increasing FFA flux and 
oxidation. And, as  hyperglycemia, this FFA-induced increase in ROS 
activates the same damaging pathways: AGEs, PKC and hexosamine 
pathway. 
Diabetic neuropathy 
General Consideration  
Diabetic neuropathy is one of most common long-term, 
complications of diabetes mellitus and is clinically present in 30-50% of 
all diabetic patients. The clinical and electro-physiological evidence of 
diabetic peripheral neuropathy is estimated to be about 70% in both type-
I and type II diabetes mellitus. 
Distal symmetrical polyneuropathy (DSPN)  is a symmetrical, 
length-dependent sensorimotor polyneuropathy attributable to metabolic 
and microvessel alterations as a result of chronic hyperglycemia exposure 
(diabetes) and cardiovascular risk covariates. The various risk factors  
were studied, which predispose to the early development of diabetic 
neuropathy. The most important-factor is the level of hyperglycemia. The 
fasting blood sugar is major determinant of neuropathy independent of 
diabetic duration, age and body mass index.
 
The high Glycosylated 
hemoglobin associated with increased incidence of distal symmetrical 
neuropathy (DSN) and DAN.Orskoy. L et al found that neuropathy only 
rarely developed in patients with Glycosylated hemoglobin below 7%.
19
.  
Classification
20,21
 
Since mixed syndromes are frequent in diabetic neuropathy it is 
very difficult to classify the diabetic neuropathy as observed by many 
workers. 
1. Bruyn and Garland Classification  
I. Symmetrical, predominantly sensory, and distal polyneuropathy  
A. Diabetic pseudotabes  
B. Hyperalgesic type  
II. Asymmetrical, predominantly motor, and often proximal neuropathy  
A. Mononeuropathy  
B. Multiple neuropathy  
C. Autonomic visceral neuropathy  
D. Radiculopathy  
2. Thomas’ Classification  
I. Symmetrical polyneuropathies  
A. Sensory or sensorimotor polyneuropathy  
B. Acute or subacute motor neuropathy  
C. Autonomic neuropathy 
II. Focal and multifocal neuropathies  
A. Cranial neuropathy  
B. Trunk and limb mononeuropathy  
C. Proximal motor neuropathy  
3. Boluton and Ward Classification  
I. Mononeuropathy  
A. Cranial  
B. Truncal  
C. Multiple  
II. Polyneuropathy  
A. Acute sensory neuropathy  
B. Chronic sensori motor  
C. Autonomic  
D. Proximal  
E. Truncal motor  
4. Classification by topography  
Somatic Neuropathies  
I. Distal Symmetric Diabetic Neuropathy  
A. Predominantly sensory  
• Small fibre (pain and temperature sensory function)  
• Larger fibre (Propricoeptive, vibrational, and muscle reflex 
sensory   function).  
• Mixed large and small fibre  
B. Predominantly motor  
• With sensory neuropathy  
• With hypoglycemia  
II. Proximal Symmetric Diabetic Neuropathy  
III. Asymmetric Diabetic Neuropathy  
A. Predominantly sensory :  Intercostal radiculopathy , Truncal 
radiculopathy 
B. Predominantly Motor : Cranial neuropathy, Peripheral 
neuropathy{Median (Carpal’s tunnel syndrome), ulnar, 
popliteal} 
C. Proxmial neuropathy  
IV. Autonomic Neuropathies  
I. Cardiovascular  
 Exercise intolerance, Cardiac denervation syndrome. 
Orthostatic regulation  
 
II. Gastrointestinal  
 Gastric emptying abnormalities, Constipation, Diabetic 
diarrhea,  Incontinence 
III. Genito-urinary  
 Bladder dysfunction, Sexual dysfunction  
IV. Counter – Regulatory  
V. Sudo Motor 
EXAMINATION SCORES FOR DIABETIC NEUROPATHY
22
 
Frequently used and accepted examination scores for diabetic 
neuropathy are the Neuropathy Disability Score (NDS) , the Neuropathy 
Impairment Score in the Lower Limbs (NISLL) , various modified NDS 
scores, the Neuropathy Deficit Score, the Michigan Neuropathy 
Screening Instrument (MNSI), and the Clinical Examination Score of 
Valk (CE-V). 
The NDS was designed for neuropathy in general. Although the 
score is well founded and complete, it is difficult to perform in clinical 
practice on patients with diabetic foot problems. Precise descriptions of 
how the tests should be performed and how items should be scored are 
lacking. The NISLL is a modification of the NDS specific for distal PNP, 
although motor activity grading is the focus and involves 64 of a 
maximum of 88 points . The NIS-LL and the Neuropathy Deficit Score 
has not been validated.Feldman et al.  developed a combination of 2 
scoring systems: the MNSI (symptom and examination score) and the 
Michigan Diabetic Neuropathy Score (neurological examination and 
nerve conduction studies). These scores do not have a separate 
examination score as advised by consensus reports. The CE-V can be 
used to examine sensory functions, tendon reflexes, and muscle strength 
in the lower extremities . The scoring systems of Feldman et al. and Valk 
et al.have been validated and are easy to perform in clinical practice. 
None of the aforementioned scores is known to be hierarchical.  
The Symptom Score (DNS), and Examination Score (DNE), which 
were designed by Meijer, are simple, reproducible, fast and easy to 
perform and were modified from the widely used Neuropathy Symptom 
Score and Neuropathy Disability Score of Dyck. 
Diabetic neuropathy symptom score 
All subjects were questioned regarding the presence or otherwise 
of symptoms, either positive or negative suggesting the presence of 
neuropathy. The questionnaire was the Diabetic Neuropathy Symptom 
DNS Score  adopted from the Neuropathy Symptom Score (NSS) of 
Dyck. 
Diabetic neuropathy symptom Score: The questions should be 
answered ‘yes’ (positive: 1 point) if a symptom occurred more times a 
week during the last 2 weeks or ‘no’ (negative: No point) if it did not. 
1. Symptoms of unsteadiness in walking? 
2. Do you have a burning, aching pain or tenderness of your legs or 
feet? 
3. Do you have pricking sensations at your legs and feet? 
4. Do you have places of numbness on your legs or feet? 
Maximum score: 4 points; 0 points- PNP absent; 1-4 points - PNP present 
THE DIABETIC NEUROPATHY EXAMINATION (DNE) SCORE 
The NDS, as the most complete and accepted score, was used for 
item selection to develop the DNE. The new instrument is the DNE, 
which is a scoring system with 8 items. It was validated in diabetic 
patients with a wide spectrum of complications. The DNE is hierarchical, 
sensitive, fast, and easy to perform in clinical practice (application takes 5 
min). 
 
 
 
Diabetic Neuropathy Examination 
Muscle strength 
1. Quadriceps femoris: extension of the knee 
2. Tibialis anterior : dorsiflexion of the foot 
Reflex 
3. Triceps surae 
Sensation: index finger 
4. Sensitivity to pinpricks 
Sensation: big toe 
5. Sensitivity to pinpricks 
6. Sensitivity to touch 
7. Vibration perception 
8. Sensitivity to joint position 
Only the right leg and foot are tested. 
Scoring from 0 to 2: 
 0 = Normal 
 1 = Mild/moderate deficit 
   •  Muscle strength: Medical Research 
      Council scale 3–4 
    •  Reflex: decreased but present 
    •  Sensation: decreased but present  
 2 = Severely disturbed/absent 
    •  Muscle strength: Medical Research 
        Council scale 0–2 
    •  Reflex: absent 
    •  Sensation: absent 
Maximum score: 16 points 
A score of > 3 indicates presence of polyneuropathy. 
Electrodiagnostic studies.
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No single reference standard defines distal symmetric 
polyneuropathy. The most accurate diagnosis of distal symmetric 
polyneuropathy comprises a combination of clinical symptoms, signs, and 
electrodiagnostic findings. Electrodiagnostic findings should be included 
as part of the case definition since they provide a higher level of 
specificity for the diagnosis. 
Electrodiagnostic studies are sensitive, specific, and validated 
measures of the presence of polyneuropathy. Electrodiagnostic 
evaluations commonly include both nerve conduction studies (NCSs) and 
needle EMG. In the diagnosis of polyneuropathy, NCSs are the most 
informative part of the electrodiagnostic evaluation. NCSs are 
noninvasive, standardized, and provide a sensitive measure of the 
functional status of sensory and motor nerve fibers. NCSs are also widely 
performed and suitable for population studies or longitudinal evaluations. 
The inclusion of NCSs in the assessment of polyneuropathy adds a higher 
level of specificity to the diagnosis.For these reasons, NCSs are included 
as an integral part of the case definition of polyneuropathy.  
The protocol for performing NCSs was determined by a structured 
consensus process. There are many previous recommendations regarding 
NCS criteria for the diagnosis of polyneuropathy, but no formal 
consensus exists. The recommendations that follow are based on 
electrophysiologic principles that combine both the highest sensitivity 
and specificity as well as the highest efficiency for the diagnosis of distal 
symmetric polyneuropathy.  
Technique of nerve conduction study
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NCS involve the application of a depolarising square wave 
electrical pulses to the skin over a peripheral nerve producing: (1) a 
propagated nerve action potential (NAP) recorded at a distant point over 
the same nerve: and (2) a compound muscle action potential (CMAP) 
arising from the activation of muscle fibres in a target muscle supplied by 
the nerve. In both cases these may be recorded with surface or needle 
electrodes.  
Motor nerve conduction studies : Motor studies are performed by 
electrical stimulation of a nerve and recording the compound muscle 
action potential (CMAP) from surface electrodes overlying a muscle 
supplied by that nerve. The CMAP is a summated voltage response from 
the individual muscle fibre action potentials. The recording electrodes are 
performed using adhesive conductive pads placed onto the skin overlying 
the target muscle. The active electrode is placed over the muscle belly 
and the reference over an electrically inactive site (usually the muscle 
tendon). A ground electrode is also placed somewhere between the 
stimulating and recording electrodes providing a zero voltage reference 
point. A supramaximal stimulus is applied to the nerve at a distal and a 
proximal site. Fastest motor nerve conduction velocity can be calculated 
as follows: FMNCV (m/s)  =  distance between stimulation site 1 and site 
2 (mm)/[latency site 2 – latency site 1 (ms)]. 
Sensory conduction studies : The sensory nerve action potential (SNAP) 
is obtained by electrically stimulating sensory fibres and recording the 
nerve action potential at a point further along that nerve. Once again the 
stimulus must be supramaximal. Recording the SNAP orthodromically 
refers to distal nerve stimulation and recording more proximally (the 
direction in which physiological sensory conduction occurs). Antidromic 
testing is the reverse. Different laboratories prefer antidromic or 
orthodromic methods for testing different nerves.. The sensory latency 
and the peak to peak amplitude of the SNAP are measured. The velocity 
correlates directly with the sensory latency and therefore either the result 
may be expressed as a latency over a standard distance or a velocity.  
  
 
Nerve Conduction Study 
 
 
 
Graph of Motor Nerve Conduction Study 
F waves : F waves (F for foot where they were first described) are a type 
of late motor response. When a motor nerve axon is electrically 
stimulated at any point an action potential is propagated in both directions 
away from the initial stimulation site. The distally propagated impulse 
gives rise to the CMAP. However, an impulse also conducts proximally 
to the anterior horn cell, depolarising the axon hillock and causing the 
axon to backfire. This leads to a small additional muscle depolarisation  
(F wave) at a longer latency. F wave abnormalities can be a sensitive 
indicator of peripheral nerve pathology, particularly if sited proximally. 
Recommended protocol for nerve conduction studies as advised by 
American association of electrodiagnostic medicine 
A simplified NCS protocol may be used for the purpose of defining 
the presence of distal symmetric polyneuropathy. However, the 
abbreviated protocol is not sufficient to determine the subtype or severity 
of the polyneuropathy. For these purposes as well as for clinical trials in 
which electrodiagnostic measures will be tracked serially, the more 
comprehensive set of NCSs is recommended.  
The simplified NCS protocol is as follows: 
1. Sural sensory and peroneal motor NCSs are performed in one lower 
extremity. Taken together, these NCSs are the most sensitive for 
detecting a distal symmetric polyneuropathy. If both studies are 
normal, there is no evidence of typical distal symmetric 
polyneuropathy. In such a situation, no further NCSs are necessary.  
2. If sural sensory or peroneal motor NCSs are abnormal, the 
performance of additional NCSs is recommended. This should 
include NCS of at least the ulnar sensory, median sensory, and ulnar 
motor nerves in one upper extremity. A contralateral sural sensory 
and one tibial motor NCS may also be performed according to the 
discretion of the examiner. Caution is warranted when interpreting 
median and ulnar studies since there is a possibility of abnormality 
due to compression of these nerves at the wrist or ulnar neuropathy at 
the elbow.  
3. If a response is absent for any of the nerves studied (sensory or 
motor), a NCS of the contralateral nerve should be performed. 
4. If a peroneal motor response is absent, an ipsilateral tibial motor NCS 
should be performed. 
The minimum case definition criterion for electrodiagnostic 
confirmation of distal symmetric polyneuropathy is an abnormality 
(≥99th or ≤1st percentile) of any attribute of nerve conduction in two 
separate nerves, one of which must be the sural nerve. 
Nerve conduction studies (NCS) are the most objective noninvasive 
measures of nerve function. They represent a valuable tool of evaluation 
of neuropathy in large clinical and epidemiological studies. In clinical 
practice, however, NCS should not be considered a substitute for careful 
clinical examination, because NCS have many pitfalls and their results 
must be interpreted in the context of clinical data. In the case small-fiber 
polyneuropathies, the main drawback of NCS is that small myelinated 
and unmyelinated nerve fibers, which are affected early in the disease 
course of diabetic neuropathy, do not contribute to the sensory action 
potential detected by routine NCS. The sensory action potential is altered 
only after involvement of larger myelinated fibers, which is often a late 
event in patients with diabetes. Electrophysiological data must, therefore, 
always be evaluated in a clinical context. 
Diabetic retinopathy 
Diabetic retinopathy is a well-characterized, sight-threatening, 
chronic microvascular complication that eventually afflicts virtually all 
patients with diabetes mellitus. Diabetic retinopathy is characterized by 
gradually progressive alterations in the retinal microvasculature, leading 
to areas of retinal non-perfusion, increased vasopermeability, and 
pathologic intraocular proliferation of retinal vessels. 
 
Epidemiology of diabetic retinopathy 
All patients with type 1 diabetes and more than 60% of patients 
with type 2 diabetes develop some degree of retinopathy after 20 years. In 
patients with type 2 diabetes, approximately 20% have retinopathy at the 
time of diabetes diagnosis and most have some degree of retinopathy over 
subsequent decades about 4% of patients younger than 30 years of age at 
diagnosis and nearly 2% of patients older than 30 years of age at 
diagnosis were legally blind.
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  Approximately 25% of patients with type 
1 diabetes have retinopathy after 5 years, with this figure increasing to 
60% and 80% after 10 and 15 years, respectively.
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Pathophysiology
 
The earliest histologic effects of diabetes mellitus in the eye 
include loss of retinal vascular pericytes (supporting cells for retinal 
endothelial cells), thickening of vascular endothelium basement 
membrane, and alterations in retinal blood flow. With increasing loss of 
retinal pericytes, the retinal vessel wall develops outpouchings 
(microaneurysms) and becomes fragile. With time, increasing sclerosis 
and endothelial cell loss lead to narrowing of the retinal vessels, which 
decreases vascular perfusion and may ultimately lead to obliteration of 
the capillaries and small vessels the resulting retinal ischemia is a potent 
inducer of angiogenic growth factors. These factors promote the 
development of new vessel growth and retinal vascular permeability. 
Proliferating new vessels in diabetic retinopathy have a tendency to 
bleed, which results in preretinal and vitreous hemorrhages and later 
macular edema. 
Risk factors 
1.  Duration of diabetes is closely associated with onset and severity 
of diabetic Retinopathy.
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2.  Lack of glycemic control. 
3.  Renal disease, as manifested by microalbuminuria and 
Proteinuria.
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4.  Hypertension.
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5.  Elevated serum lipid levels are associated with extravasated lipid 
in the retina (hard exudates) and visual loss.
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Clinical findings
31
 
Clinical findings associated with early and progressing diabetic 
retinopathy include hemorrhages or microaneurysms (H/Ma), cotton-
wool spots (CWSs), hard exudates, intraretinal microvascular 
abnormalities (IRMAs), and venous caliber abnormalities (VCABs), such 
as venous loops, venous tortuosity, and venous beading. 
The intraretinal hemorrhages can be “flame-shaped” or “dot/blot” 
like in appearance. IRMAs are either new vessel growth within the retinal 
tissue itself or shunt vessels through areas of poor vascular perfusion. It is 
common for IRMAs to be adjacent to CWSs, which are caused by micro 
infarcts in the nerve fiber layer. VCABs are a sign of severe retinal 
hypoxia. In some cases of extensive vascular loss, however, the retina 
may actually appear free of non-proliferative lesions. Such areas are 
termed “featureless retina” and are a sign of severe retinal hypoxia. 
Symptoms of diabetic retinopathy 
1)  Patient complaints of blurred vision, usually central vision and 
metamorphosia as a result of maculopathy with foveal involvement. 
2)  Black spots, floaters or sudden visual loss may be experienced by 
patients with vitreous hemorrhage, depending on quantum of bleed. 
Kanski classification of diabetic retinopathy
31
 
1. Background diabetic retinopathy 
a.  Haemorrhages (Dot and Blot, Flame shaped)  
b.  Microaneurisms (Located in inner nuclear layer) 
c.  Hard exudates (Lipoprotien and lipid filled macrophages. 
Located within the outer plexiform layer).   
d.  Retinal edema (Located between outer plexiform and inner 
nuclear layer) 
 
   
 
Background Retinopathy : Retinal microaneurysms at the posterior 
pole; FA shows scattered hyperfluorescent spots in the posterior 
fundus  
 
Pre-proliferative diabetic retinopathy : Cotton-wool spots,  
IRMA and venous changes 
 
 
Severe disc new vessels Mild new vessels elsewhere 
                        
 
 
 
 
2. Pre proliferative 
a.  Vascular changes(beading , looping) 
b.  Dark  blot haemorrhages 
c.  Cottonwool spots 
d.  Intraretinal microvascular abnormalities 
e.  Shunt vessels 
3. Proliferative 
a.  Neo vascularisation 
b.  Fibrous proliferation 
c.  Vitreous detachment and haemorrhages 
4. Maculopathy 
a.  Focal 
b.  Diffuse 
c.  Ischaemic 
d. Clinically Significant Macular Oedema (CSMO) 
Classification of diabetic maculopathy 
Intraretinal 
• Macular edema 
• Macular hard exudates 
• Macular ischaemia 
Comprehensive eye examination 
Most of the blindness associated with advanced stages of 
retinopathy can be averted with appropriate and timely diagnosis and 
therapy. 
  
 
 
 
 
 
 
 
 
 
 
Diabetic nephropathy 
Pathogenisis
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 Like other microvascular complications pathogenesis of Diabetic 
nephropathy is related to chronic hyperglycemia. The mechanisms by 
which chronic hyperglycemia leads to ESRD are :  
Yes 
Diabetes 
Has patient 
had eye exam 
since diagnose 
of diabetes?   
 
Diabetes 
type 
Age 
>10 years 
 
Ophthaimic 
follow-up  per 
patient's diabetic 
retinopathy level   
 
Refer to eye 
care provider for 
comprehensive 
eye exam  
 
Is patient  
pregnant? 
Is diabetes 
duration  
>5 years 
  
Initial 
opthaimic  
exam not yet 
required 
 
No Type 1 No 
Type 2 
No 
No 
Yes 
Yes 
a) Soluble factors (Growth factors, Angiotensin II, Endothelin, 
AGEs) 
b) Hemodynamic alteration in renal microcirculation. 
c) Structural changes in Glomerulus. 
Because only  20-40% of patients with diabetes develop Diabetic 
nephropathy, additional susceptible factors remain unidentified.  
Epidemiology 
Both type 1 and type 2 diabetes cause renal disease. Compared to 
type 1, a slightly smaller and imperfectly defined proportion of type 2 
patients progress to ESRD, but they represent more than 90% of those 
receiving renal replacement therapy with the diagnosis of diabetes. The 
distribution of renal disease due to type 2 diabetes is uneven among racial 
groups. American Indians, African Americans, and Mexican Americans 
have a greater incidence than non-Hispanic whites. Genetic 
predisposition, environmental factors, delayed diagnosis of type 2 
diabetes, and sub adequate medical care in minority groups contribute in 
undefined amounts to such disparity. 
Clinical features 
Symptoms suggestive of renal impairment : 
Oliguria, Anuria, Puffiness of face, Distension of abdomen, Pedal 
edema. 
Nephropathy in type 1 diabetes
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The course of diabetic nephropathy can be followed by two main 
variables: 
Proteinuria and GFR. 
There are five distinct stages: 
1.  Stage 1: Glomerular hyper filtration and renal enlargement. 
2.  Stage 2: Early glomerular lesions or silent stage with normal albumin 
excretion. Early glomerular lesions, consisting of glomerular 
basement membrane thickening and mesangial matrix expansion, 
characterize the second stage. Those structural changes appear 18 to 
36 months after onset of type 1 diabetes and may become prominent 
after 3.5 to 5 years. During this stage of morphologic changes, 
microalbuminuria, seen only after exercise or during episodes of very 
poor metabolic control. 
3. Stage 3: Incipient diabetic nephropathy or micro albuminuric stage 
Microalbuminuria, defined as 30-300mg per day in a 24 hour 
collection or 30-300µg/mg of creatinine in spot collection, represents 
the first laboratory evidence of diabetic renal disease. It is increased 
by hypertension, strenuous exercise, fever, poor glycemic control, and 
congestive heart failure. Therefore, a diagnosis of incipient diabetic 
nephropathy is made only when Microalbuminuria is detected in at 
least two of three urine specimens over several months. 
4. Stage 4: Clinical or Overt diabetic nephropathy: proteinuria and falling 
glomerular filtration rate: 
 Albuminuria greater than 300 µg/mg of creatinine relentless decline of 
renal function, and hypertension define the fourth stage of diabetic 
nephropathy. This stage, though variable, usually occurs 15 to 20 
years after the onset of type 1 diabetes and after 5 or more years of 
diagnosed type 2 diabetes. The amount of urinary protein can be as 
little as 500 mg, but it can reach massive proportions, such as 20 to 40 
g/24 hours. 
5. Stage 5: End-stage renal disease. 
Nephropathy in type 2 diabetes
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Although renal structural changes and severity of target organ 
damage are similar in both types of diabetes, delayed diagnosis has 
complicated the construction of the natural history of diabetic renal 
disease in type 2 diabetes. Hypetension more commonly accompanies in 
Type II Diabetes.
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Materials & Methods      
MATERIALS AND METHODS 
DESIGN 
Cross sectional study 
STUDY POPULATION 
  50  patients with type 2 diabetes attending diabetology OP in 
Coimbatore medical college hospital from September  2009 to September  
2010 were selected for this study after getting informed written  consent. 
INCLUSION CRITERIA 
Patients were included for study if they had 
o Onset of type 2 diabetes > 35 years of age. 
o Duration of diabetes > 5 yrs. 
EXCLUSION CRITERIA 
Patients were excluded from study if they had 
o Gross albuminuria. 
o Non diabetic neuropathies. 
o Non diabetic retinopathy and other chronic ophthalmological 
illness. 
Detailed  history, complete clinical examination including body mass 
index, blood pressure and neurological examination with special 
reference to neuropathic abnormalities using the criteria as stated below, 
nerve conduction studies for sensory and motor neuropathy, HbA1C, 
serum total cholesterol, ophthalmolgical examination for diabetic 
retinopathy and urine analysis for microalbuminuria  was done for all 
patients. 
TECHNIQUES  
Assessment and Definition of Diabetic Peripheral neuropathy 
In this study the diabetic neuropathy examination (DNE) score is 
used for assessment of distal symmetrical polyneuropathy. 
DIABETIC NEUROPATHY EXAMINATION(DNE) SCORE 
Muscle strength 
1. Quadriceps femoris: extension of the knee 
2. Tibialis anterior: dorsiflexion of the foot 
Reflex 
3. Triceps surae 
Sensation: index finger 
4. Sensitivity to pinpricks 
Sensation: big toe 
5. Sensitivity to pinpricks 
6. Sensitivity to touch 
7. Vibration perception 
8. Sensitivity to joint position 
Only the right leg and foot are tested. 
Scoring from 0 to 2: 
 0 = Normal 
 1 = Mild/moderate deficit 
    • Muscle strength: Medical Research 
      Council scale 3–4 
    • Reflex: decreased but present 
    • Sensation: decreased but present  
2 = Severely disturbed/absent 
    • Muscle strength: Medical Research 
        Council scale 0–2 
    • Reflex: absent 
    • Sensation: absent 
Maximum score: 16 points 
A score of > 3 indicates presence of polyneuropathy. 
Vibration Sensation: Vibration sensation is performed with the great toe 
unsupported. Vibration sensation will be tested bilaterally using a 128 Hz 
tuning fork placed over the dorsum of the great toe on the boney 
prominence of the DIP joint. Patients, whose eyes are closed, will be 
asked to indicate when they can no longer sense the vibration from the 
vibrating tuning fork.In general, the examiner should be able to feel 
vibration from the hand-held tuning fork for 5 seconds longer on his 
distal forefinger than a normal subject can at the great toe (e.g. 
examiner’s DIP joint of the first finger versus patient’s toe). If the 
examiner feels vibration for 10 or more seconds on his or her finger, then 
vibration is considered decreased. A trial should be given when the tuning 
fork is not vibrating to be certain that the patient is responding to 
vibration and not pressure or some other clue. Vibration is scored as 1) 
present if the examiner senses the vibration on his or her finger for < 10 
seconds, 2) reduced if sensed for ≥10 or 3) absent (no vibration 
detection.) 
Muscle Stretch Reflexes : The ankle reflexes will be examined using an 
appropriate reflex hammer. The ankle reflexes should be elicited in the 
sitting position with the foot dependent and the patient relaxed. For the 
reflex, the foot should be passively positioned and the foot dorsiflexed 
slightly to obtain optimal stretch of the muscle. The Achilles tendon 
should be percussed directly. If the reflex is obtained, it is graded as 
present. If the reflex is absent, the patient is asked to perform the 
Jendrassic maneuver (i.e., hooking the fingers together and pulling). 
Reflexes elicited with the Jendrassic maneuver alone are designated 
“present with reinforcement.” If the reflex is absent, even in the face of 
the Jendrassic maneuver, the reflex is considered absent. 
  
 
 
 
 
 
 
 
 
 
1
10-g Semmes-Weinstein monofilament 
 
Monofilament Testing : For this examination, it is important that the 
patient’s foot be supported (i.e., allow the sole of the foot to rest on a flat, 
warm surface). The filament should initially be prestressed (4-6 
perpendicular applications to the dorsum of the examiner’s first finger). 
The filament is then applied to the dorsum of the great toe midway 
between the nail fold and the DIP joint. Do not hold the toe directly. The 
filament is applied perpendicularly and briefly, (<1 second) with an even 
pressure. When the filament bends, the force of 10 grams has been 
applied. The patient, whose eyes are closed, is asked to respond yes if 
he/she feels the filament. Eight correct responses out of 10 applications is 
considered normal: one to seven correct responses indicates reduced 
sensation and no correct answers translates into absent sensation. 
Electrophysiological studies will be performed in all cases. The 
parameters recorded included distal latencies, amplitudes of compound 
motor action potentials (CMAP), duration of CMAP, F wave latencies 
and conduction velocities in motor nerves. In sensory nerves, latencies 
and amplitudes of the sensory nerve action potentials and their 
conduction velocities were documented. 
The presence or absence of neuropathy in these subjects was defined 
as (Simplified NCS protocol) follows: 
5. Sural sensory and peroneal motor NCSs are performed in one lower 
extremity. Taken together, these NCSs are the most sensitive for 
detecting a distal symmetric polyneuropathy. If both studies are 
normal, there is no evidence of typical distal symmetric 
polyneuropathy. In such a situation, no further NCSs are necessary.  
6. If sural sensory or peroneal motor NCSs are abnormal, the 
performance of additional NCSs is recommended. This should 
include NCS of at least the ulnar sensory, median sensory, and ulnar 
motor nerves in one upper extremity. A contralateral sural sensory 
and one tibial motor NCS may also be performed according to the 
discretion of the examiner. Caution is warranted when interpreting 
median and ulnar studies since there is a possibility of abnormality 
due to compression of these nerves at the wrist or ulnar neuropathy at 
the elbow.  
7. If a response is absent for any of the nerves studied (sensory or 
motor), a NCS of the contralateral nerve should be performed. 
8. If a peroneal motor response is absent, an ipsilateral tibial motor NCS 
should be performed. 
The minimum case definition criterion for electrodiagnostic 
confirmation of distal symmetric polyneuropathy is an abnormality 
(≥99th or ≤1st percentile) of any attribute of nerve conduction in two 
separate nerves, one of which must be the sural nerve. 
Assessment and Definition of Diabetic microvascular Complications 
Direct ophthalmoscopic examination of fundus 
Fundus examination was done and results will be classified as 
normal, background, pre-proliferative and proliferative retinopathy. It 
was confirmed by a senior ophthalmologist. 
Microalbuminuria detection was done by Albumin Creatinine Ratio 
estimation. Urinary albumin measured by rate Nephelometry and Urinary 
Creatinine measured by modified Jaffe’s method. Albumin Creatinine 
Ratio of 30-300 µg/mg of creatinine was defined as microalbuminuria;
 
a 
ratio greater than 300 µg/mg of creatinine was defined as 
macroalbuminuria.
 
 
Assessment and Definition of various risk factors 
The specific risk factors studied were age, sex, duration of 
diabetes, HbA1C, BMI, systemic hypertension and total serum 
cholesterol. In the present study the definition of systemic hypertension 
was taken as subjects with either a history of systemic hypertension on 
treatment  or  whose blood pressure measurement  shows >140/90 mm 
Hg in two different occasions . 
Total serum cholesterol >200mg/dl was taken as positive. BMI was 
calculated as 
( )
2
Weight in Kg
Height in mt
 and the normal BMI was 18.5-24.9. HbA1C 
measured by bidirectionally interfaced fully automated turbidometry by 
Roche. 
  
 
 
 
Results and Analysis                  
RESULTS AND  ANALYSIS 
AGE 
The mean age of the study subjects was 51.66 years; standard 
deviation (SD) of   11.03. Most of the patients belonged to the age group 
35-44 yrs 
Sex 
Out of 50 cases, 36 were males and 14  were females. The ratio of 
males to females was  2.6:1 
TABLE 1 
AGE AND SEX DISTRIBUTION 
Age             
(in Yrs) 
Male Female Total Percentage(%) 
35-44 12 6 18 36 
45-54 10 2 12 24 
55-64 10 5 15 30 
>65 4 1 5 10 
TOTAL 36 14 50  
18  patients (36%) in the study were in the age group of 35 – 44 
years. Of these 12 were males and 6 were females. 12 patients (24%) 
were in the age group of 45 – 54 years. Of these 10 were males and 2 
were females. 15 patients (30%) in the study were in the 55 – 64 age 
group, of these 10  were males and 5 were females. 5 patients (10%) were 
in the age group of>65 years, of these 4  were males and 1 was female. 
Most patients were between the age group of 35-44 years. 
TABLE 2 
DISTRIBUTION OF DURATION OF DIABETES  MELLITUS 
Duration of 
Diabetes (Yrs) 
Male Female Total (%) 
5-10  15 9 24(48%) 
10-15 8 3 11(22%) 
15-20 8 1 9(18%) 
>20 5 1 6(12%) 
TOTAL 36 14 50 
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 In the study population, more number of patients (24 i.e 48%) were 
having diabetes with duration 5-10 years, followed by 11 patients (22%) 
with the duration of 10 to 15 years, next 9 patients(18%) between 15 to 
20 years and only 6 patients(12%) were having duration of diabetes >20 
yrs. 
TABLE 3 
HbA1C AND DURATION ON DIABETES 
Duration of 
Diabetes 
(Years) 
HbA1C 
6-8% 
(No. of 
patients) 
8-10% 
(No. of 
patients) 
>10% 
(No. of 
patients) 
Total 
Average 
HbA1C 
5-10 20 4 0 24 7.44 
10-15 4 7 0 11 8.27 
15-20 1 8 0 9 9.22 
>20 0 2 4 6 11.13 
TOTAL 25 21 4 50  
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 Among the 4 patients who had glycosylated hemoglobin >10% all 
had duration of diabetes >20 years. The average glycosylated hemoglobin 
(HbA1C) was 7.44,8.27,9.22 and 11.33 for duration of diabetes 5-10 yrs, 
10-15 , 15-20 , >20years respectively. This shows that those patients with 
duration of diabetes more than 10 years have poorer control. 
TABLE 4 
BODY MASS INDEX 
BMI(Kg/M2) Males Females Total Percentage (%) 
18.5-24.9 30 10 40 80% 
25-29.9 4 4 8 16% 
30-34.9 2 0 2 4% 
>35 0 0 0 0 
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TABLE 5 
HYPERTENSION AND DURATION OF DIABETES 
Duration of 
Diabetes 
(Years) 
Number of Hypertensive Patients 
Male Female Total (%) 
6-10 6 1 7 33% 
11-15 4 1 5 24% 
16-20 4 1 5 24% 
>20 3 1 4 19% 
TOTAL 17 4 21  
All patients with history of hypertension on antihypertensives 
and/or whose blood  pressure while clinical examination is > 140/90 mm 
Hg on two separate occasions is included  in Hypertensive group. Out of 
total of 50 patients included in study 21 patients were found to be 
hypertensive. Out of it 17 were males and 4 were females. Out of these 21 
patients 33%,24%,24% and 19% were having duration of diabetes                 
6-10,11-15,16-20,>20 years respectively. 
TABLE 6 
DISTRIBUTION OF PATIENTS ACCORDING TO DNE SCORES 
DNE score Males Females Total (%) 
<3 15 8 23 46% 
4-8 12 1 13 26% 
9-12 6 4 10 20% 
13-16 3 1 4 8% 
According to definition those patients with DNE score > 3 is having 
diabetic peripheral neuropathy (DSPN). 
DNE score Male Female Total (%) 
<3 15 8 23 46% 
>3 21 6 27 54% 
 
 
So, in this study out of total 50 patients, 27 (54%)patients were 
found to have peripheral neuropathy. Among them 21 were males and 6 
were females. Out of total 36 males in the study  21 patients(58%) had 
DNE scores >3 and out of total 14 females  in the study 6 patients (43%) 
had DNE scores >3. 
 
 
23
27
0
5
10
15
20
25
30
DNE <3 DNE>3
CHART  4
DISTRIBUTION OF PATIENTS ACCORDING TO 
DNE SCORES
MALE
FEMALE
TOTAL
TABLE 7 
TOTAL SERUM CHOLESTEROL 
Total Cholesterol Male Female Total Percentage 
>200 mg/dl 30 8 38 76% 
<200mg/dl 6 6 12 24% 
Out of total 50 patients 38(76%) were found to have total 
cholesterol >200 mg/dl. 
TABLE 8 
DIABETIC RETINOPATHY 
Retinopathy Males Females Total Percentage 
Background 6 4 10 20% 
Pre-proliferative 5 3 8 16% 
Proliferative 2 1 3 6% 
 
Out of total 50 patients in the study,  21 (42%) patients were found 
to have diabetic retinopathy. Distribution of various types  of retinopathy 
are as given in the following table 20% ,16% and 65 of the patients with 
diabetic retinopathy had background, pre-proliferative and proliferative 
retinopathy respectively. 
 TABLE 9 
MICROALBUMINURIA 
 Males Females Total Percentage 
Microalbuminuria 
present 
21 3 24 48% 
Microlbuminuria 
not present 
15 11 26 52% 
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 Out of total 50 patients 24 (48%) had microalbuminuria. As 
mentioned before those patients with gross albuminuria were excluded  
from study.It is seen from the graph that out of total 36 male patients in 
this study  21(58%)  had microalbuminuria while out of 14 female 
patients in this study only 3(6%)  had microalbuminuria. So 
microalbuminuria is more common in males. 
TABLE  10 
NERVE CONDUCTION STUDY 
 Males Females Total Percentage(%) 
NCS Positive 22 7 29 58% 
NCS Negative 14 7 21 42% 
Nerve conduction study was done on all patients using the standard 
protocol already mentioned. By using this method 29 (58%) patients were 
found to have peripheral neuropathy (positive). Out of this 22 were males 
and 7 were females.  
TABLE 11 
COMPARATIVE ANALYSIS OF CLINICAL EXAMINATION 
SCORE(DNE) AND NERVE CONDUCTION STUDY 
                            Diabetic Peripheral Neuropathy 
 
DNE Score<3(Positive) DNE Score>3(Negative) 
Males Females Total(%) Males Females Total(%) 
NCS 
Positive 
2 1 3(10.3%) 20 6 26(89.7%) 
NCS 
Negative 
13 7 20(95.2%) 1 0 1(4.8%) 
From this table X
2
=35.338 and P value was found to be  0.001,thus 
statistically highly significant. 
From this table it can be seen that out of total 29 patients found to 
have peripheral neuropathy by nerve conduction study 26 (89.7%) of 
them had DNE  scores >3 and so only 3(10.3%) patients were found to 
have  peripheral neuropathy by nerve conduction who were missed by  
our clinical examination score. But it can also be seen from the table that 
1 patient(4.8%) who was found by nerve conduction as not having 
peripheral neuropathy was found to have DNE score >3 and thus was 
clinically positive for neuropathy. 
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TABLE 12 
DIABETIC  PERIPHERAL NEUROPATHY AND RETINOPATHY 
 Diabetic Peripheral Neuropathy 
DNE Score<3 DNE Score>3 
Males Female Total(%) Male Female Total(%) 
Diabetic 
retinopathy 
5 2 7(33.3%) 13 2 14(66.7%) 
No 
retinopathy 
10 6 16(55.2%) 8 4 13(44.8%) 
 From this table chi-square value X
2
=5.339 and P value was <0.05 
and thus this association was statistically significant. 
Out of  21 patients who were found to have  retinopathy by fundus 
examination 14 patients(66.7%) had peripheral neuropathy by clinical 
examination (DNE)score while 16 (55.2%) out of 29 patients those who 
did not have retinopathy also did not have peripheral neuropathy. 
On calculating correlation between these two variables, Pearsons 
correlation coefficient r=0.416 (p 0.05) and thus it was found that 
correlation between diabetic peripheral neuropathy and diabetic 
retinopathy was also statistically significant. 
 
 TABLE 13 
DIABETIC PERIPHERAL NEUROPATHY AND 
MICROALBUMINURIA 
 Diabetic Peripheral Neuropathy 
 DNE score<3 DNE score>3 
Male Female Total Male Female Total 
Micro 
Albuminuria 
3 1 4(16.7%) 18 2 20(83.3%) 
No 
albuminuria 
12 7 19(73.1%) 3 4 7(26.9%) 
From this table  X
2
=15.987 and P value was  0.001and thus this 
association highly significant. 
Out of  24  patients who were found to have microalbuminuria 
,20(83.3%) had peripheral neuropathy by DNE scores, while 19 (73.1%) 
out of 26 patients those who did not have microalbuminuria also did not 
have peripheral neuropathy.  
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On calculating correlation between these two variables, Pearsons 
correlation coefficient r=0.565 (p 0.01) and thus it was found that 
correlation between diabetic peripheral neuropathy and microalbuminuria 
was also statistically significant. 
 
TABLE 14 
DIABETIC PERIPHERAL NEUROPATHY AND SEX 
 Diabetic Peripheral Neuropathy 
DNE Score<3 DNE Score>3 
Males 15(41.7%) 21(58.3%) 
Females 8(57.1%) 6(42.9%) 
From this table  X
2
=0.972and P value was 0.324 and thus this 
association not statistically significant. 
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On calculating correlation between these two variables,  Pearsons 
correlation coefficient r=0.197  and thus it was found that correlation 
between diabetic peripheral neuropathy and sex was not statistically 
significant. 
TABLE 15 
DISTRIBUTION OF DIABETIC PERIPHERAL NEUROPATHY  
IN DIFFERENT AGE GROUPS 
                            Diabetic Peripheral Neuropathy 
                    DNE Score<3               DNE Score>3 
Age 
interval 
Males Females Total(%) Males Females Total(%) 
35-44 7 5 12(66.7%) 5 1 6(33.3%) 
45-54 2 1 5(41.7%) 8 1 7(58.3%) 
55-64 4 2 4(26.7%) 6 3 11(73.3%) 
>65 2 0 2(40%) 2 1 3(60%) 
From this table  X
2
=8.515 and P value was <0.05 and thus this 
association statistically significant. 
  The mean age of  patients with peripheral neuropathy was found to 
be 54.67 and the mean age of patients without peripheral neuropathy was 
found to be 46.78 . In the age groups 35-44,45-54,55-64 and >65 ,it was 
found that  out of total number of patients in each groups, 33.3%, 58.3%, 
73.3%, 60% had diabetic neuropathy respectively. 
On calculating correlation between these two variables, Pearsons 
correlation coefficient r=0.841 (p 0.05) and thus it was found that 
correlation between diabetic peripheral neuropathy and age was 
statistically significant. 
 
TABLE 16 
DIABETIC PERIPHERAL NEUROPATHY AND  DURATION OF 
DIABETES 
 
Diabetic Peripheral Neuropathy 
DNE Score<3 DNE Score>3 
Duration 
of 
diabetes 
Males Females Total(%) Males Females Total(%) 
5-10 10 5 16(66.7%) 5 4 8(33.3%) 
10-15 2 3 4(36.4%) 6 0 7(63.6%) 
15-20 2 0 2(22.2%) 6 1 7(77.8%) 
>20 1 0 1(16.7%) 4 1 5(83.3%) 
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From this table  X
2
=8.665 and P value  <0.05 was and thus  
significant. 
The mean duration of diabetes in patients with peripheral 
neuropathy was found to be 13.98 and the mean duration  in those 
without peripheral neuropathy was found to be 10.10 Among those 
patients  with duration of diabetes >20 years 83% had peripheral 
neuropathy. Similarly 78%,64%,33% of patients  with duration of 
diabetes 5-10,10-15,15-20 years  respectively had peripheral neuropathy. 
On calculating correlation between these two variables,  Pearsons 
correlation coefficient r=0.400 (p 0.01) and thus it was found that 
correlation between diabetic peripheral neuropathy and duration of 
diabetes was also statistically significant. 
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 TABLE 17 
DIABETIC PERIPHERAL NEUROPATHY AND  HbA1C LEVELS 
 
Diabetic Peripheral Neuropathy 
DNE Score<3(negative) DNE Score>3(positive) 
HbA1C(%) Males Females Total(%) Males Females Total 
6-8 11 5 16(64%) 7 2 9(36%) 
8-10 3 3 6(28.6%) 12 3 15(71.4%) 
>10 1 0 1(25%) 2 1 3(75%) 
From this table  X
2
=6.539 and P value was <0.05 and thus 
significant. 
The mean HbA1C level of patients with peripheral neuropathy was  
9.22 with and those without peripheral neuropathy was 7.65.  
On calculating correlation between these two variables,  Pearsons 
correlation coefficient r=0.337 (p 0.05) and thus it was found that 
correlation between diabetic peripheral neuropathy and HbA1C was also 
statistically significant. 
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TABLE 18 
DIABETIC PERIPHERAL NEUROPATHY AND BODY MASS 
INDEX 
 
Diabetic Peripheral Neuropathy 
DNE Score<3 DNE Score>3 
BMI(Kg/m2 Males Females Total(%) Males Females Total 
18.5-24.9 12 7 20(50%) 18 3 20(50%) 
25-29.9 2 1 3(37.5%) 2 3 5(62.5%) 
30-34.9 1 0 0 1 0 2(100%) 
>35 0 0 0(%) 0 0 0(%) 
From this table  X
2
=2.194  and P value was 0.334 and thus not 
significant.  
 The mean BMI in patients with peripheral neuropathy was 23.05  
and in those without peripheral neuropathy was 22.76. 
On calculating correlation between these two variables,  Pearsons 
correlation coefficient r=0. 197 and thus it was found that correlation 
between diabetic peripheral neuropathy and BMI was also not statistically 
significant. 
 
 
 
 
TABLE 19 
DIABETIC PERIPHERAL NEUROPATHY AND SYSTEMIC 
HYPERTENSION 
 Diabetic Peripheral Neuropathy 
           DNE Score<3               DNE Score>3 
Males Females Total Males Females Total 
Hypertensive 
1 0 3(14.3%) 16 4 18(85.7%) 
Normal BP 14 8 20(69%) 5 2 9(31%) 
 From this table  X
2
=14.661  and P value was <0.001and thus  
highly significant. 
Out of the total 21 patients who were found to have systemic 
hypertension, 18 (85.7%)had peripheral neuropathy. Also  out of total 29 
patients who were found as having normal blood pressure 20(69%)were 
not having peripheral neuropathy. 
On calculating correlation between these two variables, Pearsons 
correlation coefficient r=0.541 (p 0.05) and thus it was found that 
correlation between diabetic peripheral neuropathy and systemic 
hypertension was also statistically significant. 
TABLE 20 
DIABETIC PERIPHERAL NEUROPATHY AND  TOTAL SERUM 
CHOLESTEROL 
 
Diabetic Peripheral Neuropathy 
DNE Score<3 DNE Score>3 
Total Serum 
Cholesterol 
Males Females Total(%) Males Females Total(%) 
>200 mg/dl 12 6 18(47.4%) 16 4 20(52.6%) 
NORMAL 3 2 5(41.7%) 5 2 7(58.3%) 
 From this table  X
2
=0.119   and P value was 0.730  and thus not 
significant. 
 Out of total 38 patients who were found to be having high total 
serum cholesterol,20(53%) of them had peripheral neuropathy. But  out 
of 12 patients who were having normal serum cholesterol  7(58.3%) were 
having  peripheral neuropathy. 
On calculating correlation between these two variables, Pearsons 
correlation coefficient r=0.049 and thus it was found that correlation 
between diabetic peripheral neuropathy and total serum cholesterol was 
also not statistically significant. 
  
 
 
 
Discussion                        
 
DISCUSSION 
                Diabetic Neuropathy is one of the most common troublesome 
complications of diabetes mellitus. 
One of the aims of the present study was clinical and electrophysiological 
evaluation of diabetic peripheral neuropathy and do a comparative 
analysis. The present study used the Diabetic Neuropathy Examination 
Score (DNE), which was designed by Meijer. Nerve conduction studies 
were done according to a standard protocol as already mentioned. In the 
study it was observed that out of the 29 subjects who were found to have 
neuropathy by Nerve Conduction Studies, 26 tested positive by the DNE 
score which gave a sensitivity of 89.7%. There is statistically significant 
association between clinical examination scores(DNE) and nerve 
conduction study. Thus  it can be inferred that the clinical examination by 
the DNE scores is a simple, reliable and reproducible method of 
diagnosing diabetic peripheral neuropathy. 
Similar results were observed in various previous studies. In an 
earlier study done by M K ROY et al
35
 in Kolkata in 2002, it was found 
that the nerve conduction  studies were found to be abnormal only in 
those with clinical abnormalities as per DNE scoring. In another study  
which was done by A.MYTHILI  et al
23
 which was published in 
International Journal Of  Diabetes In Developing Countries in 2010,it was 
found that  out of the 71 subjects who were confirmed to have neuropathy 
by Nerve Conduction Studies, 59 tested positive by the DNE score which 
gave a sensitivity of 83%. Of the 29 subjects who were considered as not 
having neuropathy by the same criteria, 6 had a DNE score positive for 
neuropathy. The specificity of the DNE score was 79%. 
One study which showed results which were contrary to our 
observations done by KUMAR R et al
36
 in Delhi which showed that out 
of 50 patients of type 2 diabetes, clinical neuropathy was present in 40% 
cases, but using nerve conduction abnormalities as a measure of 
neuropathy prevalence increases to 68% and was statistically highly 
significant (p = 0.001).This disparity may be due to the fact that they used 
a different clinical scoring other than the DNE scoring used in our study,  
which might have  lesser sensitivity and specificity. 
CORRELATION BETWEEN  DIABETIC NEUROPATHY  AND 
OTHER MICROVASCULAR COMPLICATIONS 
The second aim of this study was to correlate diabetic neuropathy 
with retinopathy and microalbuminuria. For this correlation clinical 
examination scoring was used  for defining the presence or absence of 
peripheral neuropathy. As already mentioned  those patients with gross 
albuminuria and those with retinopathy due to other causes were excluded 
from study.It was found that there is statistically significant correlation 
between diabetic neuropathy and retinopathy (P<0.05) and 
microalbuminuria (P<0.001) 
This finding was similar to that observed in earlier studies. 
TESFAYE S et al
37
  in the in the European Diabetes (EURODIAB) 
Prospective Complications
 
Study showed evidence of a strong association 
between neuropathy and other
 
microvascular complications. In the study 
conducted by KUMAR R et al in Delhi it was shown that  all patients 
with diabetic retinopathy and 86% of patients with microalbuminuria 
were found to have peripheral neuropathy which were statistically 
significant. In a study by PIRART
38
 showed positive correlation between 
the occurrence of diabetic neuropathy and retinopathy. 
This strong correlation between various microvascular 
complications of diabetes further supports the fact that there is a common 
pathogenic mechanism underlying. Therefore by early detection of 
peripheral neuropathy, urgent measures can be taken to retard the 
progression of other microvascular complications. 
 
 
CORRELATION BETWEEN  PERIPHERAL NEUROPATHY 
AND VARIOUS RISK FACTORS 
From the present study it was found that there was  statistically 
significant  correlation between diabetic peripheral neuropathy with age 
(p< 0.05), duration of diabetes (P<0.01), HbA1C levels(P< 0.05) and 
systemic hypertension (P<0.01).It was also found that the correlation of 
diabetic peripheral neuropathy with sex, BMI total serum cholesterol was 
not statistically significant. 
One of the earlier study to establish relation between glycemic 
control and neuropathy performed by PIRART
38
 which showed that poor 
control was associated with a higher incidence of neuropathy. Intensive 
glycemic control in the DCCT study showed decreased incidence of 
diabetic neuropathy to 3% in intensively treated patients compared to 
10% in group that received conventional treatment.
5 
HOLMAN et al
39
, 
concluded that tight control of diabetes retarded or reversed the 
progression of the neuropathy.
 
On the other hand Service et al
40
, found no 
such correlations. However majority of the authorities DYCK et al, 
favour the view that poor control of diabetes is associated with an 
increased risk of neuropathy. This is further substantiated by our study by 
the strong correlation of neuropathy with duration of diabetes and  
HbA1C . 
TESFAYE S et al
 
showed that the incidence of neuropathy is 
associated
 
with potentially modifiable cardiovascular risk factors, 
including
 
a raised triglyceride level, body-mass index, smoking, and 
hypertension. In the study by KUMAR et al  it was found that in type 2 
diabetics, age, duration of diabetes, microalbuminuria and retinopathy 
were strongly correlated with deterioration of nerve function 
With respect to systemic hypertension and age the observations 
made in the present study was similar to  previous studies. Aggressive 
treatment of hypertension
 
is now standard clinical practice in the 
management of nephropathy
 
and retinopathy, and the results of the 
present study make a
 
case for clinical trials to confirm the efficacy of 
antihypertensive
 
agents and possibly other strategies for cardiovascular 
risk
 
reduction in slowing the progression of neuropathy. 
  In this  study out of total 50 patients, only two of them had BMI 
>30.That may account for the disparity in the observations in our study 
compared to Tesfaye.s.et al.  In the present study correlation was done 
between total cholesterol levels and neuropathy while in Tesfaye. S .et al 
they compared the triglyceride levels .Furthermore there may be other 
factors influencing serum cholesterol which was not taken into 
consideration in the present study. In the previous studies correlations 
were done with peripheral neuropathy assessed by nerve conduction 
studies, but in the present study peripheral neuropathy assessed by 
clinical scoring was used for comparison. All these factors may be 
responsible for  the disparity. 
 
  
 
 
 
Conclusions           
 
 
CONCLUSIONS 
1. There is statistically significant association between clinical 
examination scores(DNE) and nerve conduction study. Thus  it can 
be inferred that the clinical examination by the DNE scores is a 
simple, reliable and reproducible method of diagnosing diabetic 
peripheral neuropathy. 
2. There is statistically significant correlation of diabetic neuropathy 
with other microvascular complications namely diabetic 
retinopathy(P<0.05)and microalbuminuria (P<0.001) 
3. There was  statistically significant  correlation between diabetic 
peripheral neuropathy with age (p< 0.05), duration of diabetes 
(P<0.01), HbA1C levels (P<0.05) and systemic hypertension 
(P<0.01). It was also found that the correlation of diabetic 
peripheral neuropathy with sex, BMI, total serum cholesterol was 
not statistically significant. 
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Annexures 
PROFORMA 
PRELIMINARY DATA OF THE PATIENT 
 
 
NAME :  DATE : 
 
AGE/SEX :                                                 I.P. NO. : 
 
DEPARTMENT :                  UNIT : 
 
WARD :            
                                                                                    
OCCUPATION : 
 
DATE OF ADMISSION :       
 
DATE OF DISCHARGE: 
 
ADDRESS : 
 
PRESENTING COMPLAINTS : 
5. Symptoms of unsteadiness in walking? YES/No 
6. Do you have a burning, aching pain or tenderness of your legs or 
feet? YES/NO 
7. Do you have pricking sensations at your legs and feet? YES/NO 
8. Do you have places of numbness on your legs or feet? YES/NO 
PAST HISTORY: 
Previous H/o Illness 
 
TREATMENT HISTORY: 
 
PERSONAL HISTORY : 
 
H/o Alcohol Intake : Yes                       No 
Duration : 
Quantity : 
 
H/o of Smoking :     Yes                        No 
Duration : 
Quantity : 
 
H/o of Weight Loss : 
 
FAMILY HISTORY : 
 
Diabetes :                 Yes                        No 
 
Hypertension :         Yes                         No 
 
 
GENERAL PHYSICAL EXAMINATION: 
Height: Cms. 
Weight: Kgs 
 
B.M.I. : 
 
Pallor -                     Yes                        No 
 
Icterus -                    Yes                        No 
 
Clubbing -                Yes                        No 
 
Cyanosis -                Yes                        No 
 
Lymphadenopathy - Yes                        No 
 
 
 
VITAL PARAMETERS: 
Pulse _____________________ BP _______________ 
Respiratory Rate _____________________  
Temperature _______________ 
 
SYSTEMIC EXAMINATION: 
CENTRAL NERVOUS SYSTEM: 
Higher Mental functions : 
 
Cranial Nerves : 
Fundoscopy : 
  
Muscle strength                                    0                1                   2 
                                                                                 
1. Quadriceps femoris:  
 
      2. Tibialis anterior:  
 
 
Reflex 
      3. Triceps surae 
 
Sensation: index finger 
 
    4. Sensitivity to pinpricks 
 
Sensation: big toe 
                                                                                                         
9. Sensitivity to pinpricks 
 
 
10. Sensitivity to touch 
 
 
11. Vibration perception 
 
 
      8. Sensitivity to joint position 
 
 
CARDIOVASULAR SYSTEM 
Positive Findings: 
RESPIRATORY SYSTEM 
Positive Findings: 
GASTROINTESTINAL SYSTEM 
Positive findings: 
INVESTIGATIONS  
 
1. Blood a. Hb%            c. T.C.  
              b. ESR             d. DC-N/LM/E/B.  
 
2. Urine  
a. Quantity in 24 hours  
 
b. Colour of the urine  
 
c. Specific gravity  
 
d. Reaction: Acidic / Alkaline  
 
e. Sugar  
 
                 f. Albumin / Microalbuminuria detection by 
                  Albumin creatinine ratio estimation 
 
g. 24 hrs urine protein  
 
h. Ketone bodies  
 
i. Microscopic  
 
4. Diabetic Profile :  
RBS  
FBS  
PPBS (2 hrs. after food) 
HbAIc 
 
5.Total S. Cholesterol :  
 
6. Renal Function Tests:  
    B. Urea.  
    S. Creatinine  
    S. Sodium  
    S. Potassium 
  
7. ECG in all 12 leads : 
 
8. Chest X-Ray  
 
9.NERVE CONDUCTION STUDY: 
SL NO AGE SEX IP NO
SYMPTOM 
SCORE
PAST 
HISTORY
FAMILY 
HISTORY
DURATION 
OF 
DIABETES
SMOKING ALCOHOLISM BMI
PULSE 
RATE
SYSTEMIC 
HYPERTENSION
CLINICAL
(DNE)
SCORES
CVS FUNDUS
MICRO
ALBUMINURIA
FBS PPBS HBA1C
TOTAL CHOLESTEROL
>200mg/dl
ECG
CHEST 
XRAY
NERVE 
CONDUCTION 
STUDY
1 53 F 60224 2 NS + 6 NO NO NL 70 NO 6  N NL NO 233 358 6.1 NO N  N +
2 46 M 1447 1 NS + 6 NO NL 80 NO 2  N NL NO 168 215 7 NO N  N -
3 38 M 40991 1 NS - 8 NO YES NL 86 NO 2  N NL NO 291 336 7.3 NO N  N -
4 63 F 3983 1 NS + 16 NO NO 26.9 84 NO 1  N NPR YES 145 170 9.7 YES N  N -
5 63 F 4907 4 SHT + 22 NO NO 26.6 78 YES 14  N NPR YES 180 260 9.2 YES CAD  N +
6 62 M 27744 3 NS + 25 YES NO NL 76 YES 13  N NPR YES 160 190 13 YES N  N +
7 53 M 8453 1 NS + 7 NO YES NL 80 NO 1  N BR NO 154 206 8.6 YES N  N -
8 58 M 23749 3 NS + 21 NO NI 34.5 70 YES 10  N BR YES 168 204 13 YES N  N +
9 49 M 8442 1 NS - 12 YES YES NL 78 YES 5  N NL YES 125 170 7.2 YES N  N +
10 74 M 28394 2 SHT + 18 NO YES NL 86 YES 6 AS NL YES 136 204 6.9 YES N  N +
11 63 M 7453 1 SHT + 7 YES NO NL 74 YES 8  N BR YES 158 324 8.2 YES N  N +
12 62 F 29839 1 NS + 14 NO NO NL 80 NO 1  N NL NO 146 216 6.6 NO N  N -
13 40 M 3245 3 NS - 19 YES YES 28.6 86 YES 13  N NPR YES 175 178 9.5 YES CAD  N +
14 52 M 678 1 NS - 6 NO NO NL 84 NO 2  N NL NO 233 168 8.7 YES N  N -
15 43 M 14789 1 NS + 18 YES YES NL 90 YES 7  N BR YES 136 180 6.4 YES N  N +
16 63 M 9744 2 SHT + 23 NO NO 32.9 84 YES 8  N BR YES 148 186 12 YES N  N +
17 42 M 45566 1 SHT - 21 YES YES NL 86 YES 2  N BR YES 154 176 11 YES N  N +
18 64 M 23747 1 NS + 11 NO YES NL 96 YES 6  N NL YES 128 190 6.3 YES N  N +
19 38 F 8887 1 NS - 13 NO NO NL 76 NO 2  N NPR NO 148 204 7.2 NO N  N -
20 40 M 9433 1 NS + 16 YES YES NL 78 NO 4  N NPR YES 152 216 7.1 YES N  N +
21 36 F 7920 1 NS + 7 NO NO NL 72 NO 3  N NL NO 204 358 6.9 YES N  N -
22 62 M 67889 1 NS - 6 YES YES NL 68 NO 2  N NL NO 190 186 7.9 YES N  N -
23 53 M 2847 1 SHT - 13 YES NO NL 70 YES 8  N NL YES 176 176 8.9 YES N  N +
24 70 M 71234 1 NS + 14 NO YES NL 68 NO 4  N NL NO 186 190 7.3 NO N  N -
25 42 M 63821 1 NS - 7 YES YES NL 72 NO 3  N BR NO 175 170 7.2 YES N  N -  
SL NO AGE SEX IP NO
SYMPTOM 
SCORE
PAST 
HISTORY
FAMILY 
HISTORY
DURATION 
OF 
DIABETES
SMOKING ALCOHOLISM BMI
PULSE 
RATE
SYSTEMIC 
HYPERTENSION
CLINICAL
(DNE)
SCORES
CVS FUNDUS
MICRO
ALBUMINURIA
FBS PPBS HBA1C
TOTAL CHOLESTEROL
>200mg/dl
ECG
CHEST 
XRAY
NERVE 
CONDUCTION 
STUDY
26 42 F 7839 1 NS + 9 NO NO NL 76 NO 2  N NL NO 233 260 8.2 YES N  N +
27 61 M 7364 1 SHT + 8 NO NO NL 84 YES 6  N NL NO 136 190 9.5 NO LVH  N +
28 50 M 7942 2 NS + 19 YES NO NL 86 NO 9  N BR YES 148 206 9.5 YES N  N +
29 38 M 48289 2 NS - 20 NO NO NL 74 YES 12  N NPR YES 154 204 6.9 YES  N +
30 39 F 66879 1 NS + 7 NO NO NL 80 NO 2  N NL NO 128 210 6.7 YES N  N -
31 48 M 56726 3 SHT + 20 YES NO 27.7 86 YES 16  N PR YES 186 178 9.9 YES CAD  N +
32 48 M 1388 1 NS + 6 NO YES NL 84 NO 2  N NL NO 136 180 6.6 YES N  N -
33 62 F 3744 2 NS - 8 NO NO NL 72 NO 10  N NL NO 240 324 9.3 YES N  N +
34 59 M 8893 1 SHT + 7 YES NO NL 88 YES 4  N BR YES 136 158 7.3 YES N  N +
35 41 M 29848 1 NS + 6 NO YES NL 68 NO 1  N NL NO 236 360 6.4 YES N  N -
36 47 M 14589 3 SHT - 13 NO NO 25.8 68 YES 10  N PR YES 158 196 9 YES N  N +
37 68 M 546 1 NS - 19 YES NO NL 72 NO 2  N NL NO 146 204 7.5 YES N  N -
38 38 F 46821 1 NS + 6 NO NO NL 76 NO 2  N NL NO 175 210 6.3 YES N  N -
39 60 M 9848 1 NS + 15 NO YES NL 84 NO 9  N NL NO 138 178 10 NO N  N +
40 36 M 23466 1 NS + 10 YES NO NL 86 NO 2  N NL NO 291 180 6.1 YES N  N -
41 60 F 36787 2 NS - 7 YES NO NL 74 NO 9  N NL NO 185 206 8.1 NO N  N +
42 58 M 8756 1 NS + 6 NO NO NL 78 NO 1  N NL NO 180 188 7.2 YES N  N -
43 72 M 7632 1 NS + 7 YES YES NL 76 NO 2 AS NL NO 204 180 7.7 YES N  N -
44 42 F 64233 4 SHT + 8 NO NO NL 80 NO 10  N NL YES 235 310 9.5 YES N  N +
45 40 M 8764 1 SHT - 14 NO NO 26.3 70 YES 3  N NPR YES 176 196 9 YES N  N -
46 68 F 4568 4 NS + 6 NO NO NL 78 NO 11 AS NL NO 142 170 9.3 NO N  N +
47 47 M 46787 1 SHT - 12 YES YES NL 86 YES 4  N NL YES 146 168 9.1 NO LVH  N +
48 43 M 5688 1 NS + 6 NO NO 28.9 74 YES 1  N NL YES 140 184 10 YES N  N +
49 39 M 23667 4 SHT + 21 YES YES 26.2 80 YES 14  N BR YES 168 198 9.2 YES N  N +
50 48 F 34566 1 NS + 12 NO NO NL 76 NO 2  N PR NO 246 310 6.2 NO N  N -
CONSENT FORM 
Yourself Mr/Mrs/Ms  _________________ are  being asked to be a 
participant in the study titled – “EVALUATION OF PERIPHERAL 
NEUROPATHY IN TYPE 2 DIABETES MELLITUS AND ITS 
CORRELATION WITH OTHER MICROVASCULAR 
COMPLICATIONS by Dr Neetha Balaram, Post Graduate student, 
Department of General Medicine,Coimbatore Medical College. You are 
eligible after looking into inclusion  criteria. You can ask any questions 
you may have  before  agreeing to participate.  
Purpose of the research  
• To evaluate peripheral neuropathy in type 2 diabetes patients by 
clinical examination and  electrophysiologicaly by nerve conduction 
study and thus do a comparitive analysis. 
• To study the correlation of diabetic peripheral neuropathy with 
age,sex,duration of diabetes,body mass index,hypertension and 
hypercholestrolemia  
• To study the correlation of diabetic peripheral neuropathy with other 
microvascular complications by assessing microalbuminuria and 
retinopathy 
Procedures involved  
This research is intended to study type 2 diabetes mellitus patients 
for evaluation of peripheral neuropathy by clinical examination and by 
nerve conduction study and to correlate with other microvascular 
complications and risk factors. 
Decline from participation  
You have the option to decline from participation in the study 
without any discrimination and you will be treated as per the existing 
protocol for your condition. 
Privacy and confidentiality  
Privacy of individual will be respected and any information about 
you or provided by you during the study will be kept strictly confidential. 
Authorization publish results  
Results of the study may be published for scientific purposes and / 
or presented to scientific groups; however you will not be identified. 
Statement of Consent   
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to 
me and I may ask questions at any time.  
 
________________________________            _______________  
Signature of Left Hand thumb Impression           Date  
(Volunteer Subject)       
 
 
______________________________     ________________  
Signature (Witness)           Date  
 
ABBREVIATIONS 
HbAIC - Glycosylated Hemoglobin 
DIP - Distal Interphalangeal Joint    
DNE  - Diabetic Neuropathic Examination 
Hz  - Hertz 
CMAP - Compound Muscle Action Potential 
NCS - Nerve Conduction Study    
BMI  - Body Mass Index 
MODY - Maturity Onset Diabetes Of The Young 
DM  - Diabetes Mellitus 
ATP  - Adenosine Triphosphate 
AGE  - Advanced Glycation Endproducts 
DSPN - Diabetic Symmetrical Polyneuropathy 
DAN   - Diabetic Autonomic Neuropathy 
NADH - Nicotinamide Adenine Dinucleotide 
NADPH  - Nicotinamide Adenine Dinucleotide Phosphate 
ESRD - End Stage Renal Disease 
FBS - Fasting Blood Sugar 
PPBS - Post Prandial Blood Sugar 
 
  
 
